Humacyte (HUMA) Expected to Announce Earnings on Friday

Humacyte (NASDAQ:HUMA) will likely be announcing its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Humacyte Stock Down 13.3 %

HUMA stock opened at $2.88 on Wednesday. The business has a 50 day moving average of $3.76 and a 200 day moving average of $4.57. Humacyte has a twelve month low of $2.75 and a twelve month high of $9.97. The firm has a market cap of $362.47 million, a PE ratio of -2.15 and a beta of 1.36.

Wall Street Analysts Forecast Growth

HUMA has been the topic of a number of research analyst reports. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Humacyte currently has an average rating of “Buy” and a consensus target price of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.